timothy sykes logo
TGTX Stock Jumps As Briumvi Pipeline Momentum Accelerates Thumbnail
G Google News

TGTX Stock Jumps As Briumvi Pipeline Momentum Accelerates

TIM SYKES•UPDATED JUN. 10, 2026, 1:01 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

TG Therapeutics Inc. stocks have been trading up by 9.96 percent following highly positive news on its multiple sclerosis drug.

Key Takeaways

  • A post‑hoc pooled analysis from the Phase 3 ULTIMATE trials showed Briumvi beating teriflunomide on clinical and MRI outcomes in treatment‑naive relapsing MS patients, including early‑stage disease.
  • The Phase 3 ENHANCE study confirmed a single 600 mg Day 1 Briumvi infusion is bioequivalent to the current two‑step start, with similar safety and MRI outcomes, backing a supplemental BLA filing in 2H 2026.
  • A high‑concentration subcutaneous Briumvi for MS showed >60% bioavailability, modeled non‑inferior exposure with quarterly or every‑other‑month dosing, and clean safety, with Phase 3 data expected in late 2026/early 2027 and potential approval around 2028.
  • Early myasthenia gravis data for subcutaneous Briumvi showed rapid MG‑ADL improvements and consistent safety, supporting a Phase 2 maintenance trial after efgartigimod induction.
  • TGTX shares have repeatedly spiked on these updates, jumping 10–11% on SC MS data and trading near $40–48 as traders bid up the Briumvi story.

Candlestick Chart

Live Update At 11:32:15 EDT: On Wednesday, June 10, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 9.96%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TGTX is trading like a momentum biotech, but under the hood there is a real business taking shape. Over the last several sessions, TG Therapeutics stock has pushed from the high‑$30s to the high‑$40s, with the most recent close near $47.73 after a strong intraday run from $43.37. That is a sharp, news‑driven move, not a slow grind.

On the tape, intraday 5‑minute candles show TGTX opening with a gap and then stair‑stepping higher, with multiple pushes into the $48–49 area before consolidating just under the highs. That intraday action tells traders there is aggressive dip‑buying and very little profit‑taking so far.

Fundamentally, TGTX posted quarterly revenue of about $204.9M, with gross margin near 92.6%. That kind of margin profile is classic specialty pharma and supports the Briumvi story. Net income for the quarter was roughly $19.8M, translating to diluted EPS around $0.12 and a trailing P/E near 11.8, which is low for a high‑growth biotech.

The balance sheet shows about $442.2M in cash and $751.7M in long‑term debt, but a current ratio of 5.8 gives TGTX solid near‑term flexibility. Free cash flow is still slightly negative, yet returns on equity and capital are elevated, signaling that every dollar put behind Briumvi is pulling weight.

More Breaking News

For active traders, that mix of rapid top‑line growth, fat margins, and a strong chart explains why TGTX keeps attracting momentum flows around each data headline.

Why Traders Are Locked In On TGTX Right Now

This entire TGTX move is being driven by one core asset: Briumvi. The company has stacked several positive readouts in a row, and traders are treating it like a rolling catalyst setup.

First, efficacy. TG Therapeutics ran a post‑hoc pooled look at its Phase 3 ULTIMATE I & II trials. Briumvi delivered significantly better clinical and MRI outcomes than teriflunomide in treatment‑naive relapsing MS, including patients treated early in the disease course. That matters. Teriflunomide is a standard oral therapy. Showing superiority there positions Briumvi as a serious contender for newly diagnosed MS patients, not just a niche option.

Second, convenience. The Phase 3 ENHANCE trial showed that a single 600 mg Day 1 infusion of Briumvi is bioequivalent to the currently approved two‑infusion start. Safety and MRI outcomes lined up, and TG Therapeutics plans a supplemental BLA filing in 2H 2026. For real‑world neurology practices, one infusion day instead of two is a big deal. Less chair time. Less scheduling friction. That can quietly boost adoption and adherence over time, and traders know it.

Third, the pipeline around the core asset. TGTX released positive Phase 1 data for a high‑concentration, low‑volume subcutaneous Briumvi in relapsing MS, showing >60% bioavailability versus IV and modeled non‑inferior exposure for quarterly and every‑other‑month dosing, with similar B‑cell depletion and a clean safety profile. Management and analysts see this as the gateway to at‑home self‑administration. Phase 3 is fully enrolled, with topline data targeted for late 2026 or early 2027 and potential approval around 2028.

The market reaction has been loud. On the SC MS data, TGTX ripped more than 10–11% in some sessions and saw premarket gains above 5%. When the company announced early myasthenia gravis data and a Phase 2 maintenance trial using Briumvi after efgartigimod, shares ticked higher again, roughly 2.5% premarket. Even the intraday move to around $40.53 on a 10.6% gain lined up with this news flow.

For day traders and swing traders, this pattern is key: every time TG Therapeutics adds a new, derisking data point on Briumvi — better dosing, new indication, or superior outcomes — TGTX gets another leg higher on heavy volume. That is exactly the type of repeated catalyst pattern the Sykes‑style trading community hunts.

Conclusion

TGTX is not a quiet biotech anymore. TG Therapeutics has lined up a chain of bullish data points around Briumvi, and the stock is responding with classic breakout behavior. A superior efficacy signal versus teriflunomide in treatment‑naive MS, a streamlined one‑day infusion regimen from ENHANCE, subcutaneous Briumvi pushing toward at‑home dosing, and a new myasthenia gravis angle — together, they turn Briumvi into a full franchise, not just a single label.

For traders, that means the story has layers. Near term, TGTX trades on momentum and news spikes. Medium term, the Phase 3 SC MS readout in late 2026/early 2027 stands out as a calendar catalyst. Longer term, potential approval around 2028 and an expanded addressable market if at‑home dosing launches become the bigger narrative.

The numbers back the story: strong revenue growth, rich margins, and a war chest that gives TG Therapeutics time to execute. But this is still a biotech ticker, and that means volatility. Strong up days on news can be followed by sharp pullbacks as traders lock in wins or react to any negative headline.

The core lesson is timeless. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your preparation — study the catalyst, study the chart, and always be ready to cut losses fast.” As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.”. With TGTX, the catalysts are clear, the chart is hot, and prepared traders are watching every headline. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading TGTX

Millionaire's
POV on TGTX

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”